FindTrial
Sign In

To evaluate the disease severity of Psoriasis using blood samples.

To evaluate the level of IL-17 and its correlation with disease severity in Psoriasis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030667
Enrollment
52
Registered
2021-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L40-L45- Papulosquamous disorders

Interventions

Intervention1: NIL: NIL

Sponsors

Father Muller Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients clinically diagnosed to have psoriasis Healthy volunteers

Exclusion criteria

Exclusion criteria: Individuals with other pre-existing skin disorders Individuals already on IL-17 inhibitors Individuals not willing to participate in the study

Design outcomes

Primary

MeasureTime frame
If IL-17A levels 3.9 ng/ml , significantTimepoint: Il-17 levels and severity of skin lesions using Psoriasis area severity index will be assessed at single visit.—

Secondary

MeasureTime frame
Whether IL-17 values truly reflect the severity of psoriasis in an individual.Timepoint: The severity of psoriasis and IL-17 level will be assessed on a single visit only.—

Countries

India

Contacts

Public ContactAnnabel Jose

Father Muller Medical College

rameshderma@gmail.com9845084224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026